Literature DB >> 30631098

Successful treatment of two relapsed/refractory t(8;21) acute myeloid leukemia patients by CD19-directed chimeric antigen receptor T cells.

Changju Qu1,2,3, Zheng Li1,2,3, Liqing Kang4,5, Ying Wang6, Haiping Dai1,2,3, Jia Yin1,2,3, Guanghua Chen1,2,3, Mingqing Zhu1,2,3, Li Yao1,2,3, Ting Xu1,2,3, Xiaopeng Tian1,2,3, Yang Xu1,2,3, Jia Chen1,2,3, Xiaming Zhu1,2,3, Lei Yu4,5, Depei Wu1,2,3, Xiaowen Tang7,8,9.   

Abstract

Entities:  

Year:  2019        PMID： 30631098     DOI： 10.1038/s41409-018-0423-y

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  2 in total

Review 1.  Treatment of AML Relapse After Allo-HCT.

Authors:  Jonathan A Webster; Leo Luznik; Ivana Gojo
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

2.  Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.

Authors:  Changju Qu; Rui Zou; Peng Wang; Qian Zhu; Liqing Kang; Nana Ping; Fan Xia; Hailing Liu; Danqing Kong; Lei Yu; Depei Wu; Zhengming Jin
Journal:  Front Immunol       Date:  2022-08-17       Impact factor: 8.786
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.